Therapy-related acute myeloid leukemia (t-AML), defined as AML arising from prior
cytotoxic, radiation, or immunosuppressive therapy for an unrelated disease, accounts for …

The treatment of acute myeloid leukemia (AML) has evolved over the past few years with the
advent of next-generation sequencing. Targeted therapies alone or in combination with low …

CPX-351 and venetoclax and azacitidine (ven/aza) are both indicated as initial therapy for
acute myeloid leukemia (AML) in older adults. In the absence of prospective randomized …

To investigate the efficacy and toxicities of CPX-351 outside a clinical trial, we analyzed 188
patients (median age 65 years, range 26–80) treated for therapy-related acute myeloid …

The development and approval of novel substances have resulted in substantial
improvements in the treatment of acute myeloid leukemia (AML). In the current era of novel …

The benefit of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients
with acute myeloid leukemia (AML) aged> 60 years remains a matter of debate, notably …

Simple Summary The better understanding of disease biology, the availability of new
effective drugs and the increased awareness of patients' heterogeneity in terms of fitness …

CPX-351, a liposomal combination of cytarabine plus daunorubicin, has been approved for
the treatment of adults with newly diagnosed, therapy-related acute myeloid leukemia (AML) …

Abstract CPX-351, a dual-drug liposomal encapsulation of daunorubicin/cytarabine in a
synergistic 1: 5 molar ratio, is approved for the treatment of adults with newly diagnosed …

Simple Summary Assessment of measurable residual disease (MRD) identifies small
numbers of acute myeloid leukemia (AML) cells that may remain after initiating treatment …